Pulmonary administration of soluble complement receptor-1 (sCR1) and its derivatives
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 2, 2001
Grant Date -
N/A
app pub date -
Aug 11, 1995
filing date -
Feb 12, 1993
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A method is disclosed for treating diseases or disorders involving complement by pulmonary administration of complement inhibitory proteins such as soluble complement receptor type 1 (sCR1). The present invention relates to the direct treatment of certain complement related disorders by administering complement inhibitory proteins via the pulmonary route, in particular, by direct delivery to the lungs by aerosolization of a complement inhibitory protein and subsequent inhalation.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully